0RQO Stock Overview
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Bonesupport Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 325.60 |
| 52 Week High | SEK 404.40 |
| 52 Week Low | SEK 217.40 |
| Beta | 0.91 |
| 1 Month Change | -3.27% |
| 3 Month Change | -15.89% |
| 1 Year Change | 46.34% |
| 3 Year Change | 617.18% |
| 5 Year Change | 1,223.58% |
| Change since IPO | 1,450.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RQO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -1.0% | 0.2% | 0.2% |
| 1Y | 46.3% | -11.7% | 6.3% |
Return vs Industry: 0RQO exceeded the UK Biotechs industry which returned -11.7% over the past year.
Return vs Market: 0RQO exceeded the UK Market which returned 6.3% over the past year.
Price Volatility
| 0RQO volatility | |
|---|---|
| 0RQO Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.0% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0RQO has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0RQO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 135 | Emil Billbäck | www.bonesupport.com |
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management.
Bonesupport Holding AB (publ) Fundamentals Summary
| 0RQO fundamental statistics | |
|---|---|
| Market cap | SEK 21.85b |
| Earnings (TTM) | SEK 133.75m |
| Revenue (TTM) | SEK 898.73m |
163.4x
P/E Ratio24.3x
P/S RatioIs 0RQO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RQO income statement (TTM) | |
|---|---|
| Revenue | SEK 898.73m |
| Cost of Revenue | SEK 66.48m |
| Gross Profit | SEK 832.25m |
| Other Expenses | SEK 698.50m |
| Earnings | SEK 133.75m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 24, 2025
| Earnings per share (EPS) | 2.03 |
| Gross Margin | 92.60% |
| Net Profit Margin | 14.88% |
| Debt/Equity Ratio | 0% |
How did 0RQO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 03:10 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bonesupport Holding AB (publ) is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Maria Vara Fernández | Bryan Garnier & Co |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |